Morocco

Edit

Edit

Edit

Edit

  • Summary and chart analysis
  • Ethics Committees
  • National Documents
  • Local Guidelines
  • Ethics Review Process Map
  • Ethics Review Process Brief
Legend:
National REC
Institutional REC

 

 

 

This page does not yet have information.

Heath Research Web is a public platform for information on research for health and development, it depends on contributions and participation from all who are interested in promoting health, health equity and development.

Please help Morocco populate its page

 

1

Choose your user profile

2

Create your account

3

Activate your account

4

Start using HRWeb
 
Document
 ArrĂŞtĂ© du ministre de la santĂ© n° 902-08 du 17 rejeb 1429 (21 juillet 2008) fixant les normes techniques d'installation, de salubritĂ© et de surface relatives au local devant abriter une officine de pharmacie ainsi que les normes techniques relatives
ArrĂŞtĂ© du ministre de la santĂ© n° 902-08 du 17 rejeb 1429 (21 juillet 2008) fixant les normes techniques d'installation, de salubritĂ© et de surface relatives au local devant abriter une officine de pharmacie ainsi que les normes techniques relatives aux Ă©tablissements pharmaceutiques.  - (doc, 109 Kb)
 Dahir n° 1-06-151 du 30 chaoual 1427 (22 novembre 2006) portant promulgation de la loi n° 17-04 portant code du mĂ©dicament et de la pharmacie.
contenant: Chapitre 1: DĂ©finitions:6 articles. Chapitre 2:section I:Dispositions relatives aux mĂ©dicaments jusqu'au l'article 17, Section II :Dispositions relatives Ă  la fabrication, Ă  l?importation, l?exportation, Ă  la vente en gros et Ă  la distribution en gros des mĂ©dicaments,jusqu'au l'article 28, Section III:Dispositions relatives Ă  la dispensation des mĂ©dicaments,jusqu'au l'article 37, Section IV:De la publicitĂ© relative aux mĂ©dicaments,jusqu'au l'article 37, jusqu'au l'article 49, Section V:Règles relatives Ă  la conservation des mĂ©dicaments, Ă  leur transport et Ă  la destruction des mĂ©dicaments impropres Ă  la consommation, jusqu'au l'article 51, Chapitre III:Des produits pharmaceutiques non mĂ©dicamenteux,jusqu'au l'article 54.,   - (doc, 182.5 Kb)
 DAHIR portant loi n° 1-75-453 du 25 hija 1396 (17 dĂ©cembre 1976)
DE L'ORDRE DES PHARMACIENS  - (pdf, 59.75 Kb)
 DECRET n. 2-63-486 du 9 chaabane 1383 (26 dĂ©cembre 1963) approuvant et
DEVOIRS GENERAUX DES PHARMACIENS  - (pdf, 34.48 Kb)
 DĂ©cret n° 2-07-1064 du 5 rejeb 1429 (9 juillet 2008) relatif Ă  l'exercice de la pharmacie, Ă  la crĂ©ation et Ă  l'ouverture des officines et des Ă©tablissements pharmaceutiques.
DĂ©cret n° 2-07-1064 du 5 rejeb 1429 (9 juillet 2008) relatif Ă  l'exercice de la pharmacie, Ă  la crĂ©ation et Ă  l'ouverture des officines et des Ă©tablissements pharmaceutiques.  - (doc, 244 Kb)
 DĂ©cret n° 2-12-198 du 21 rejeb 1433 (12 juin 2012) relatif Ă  la bioĂ©quivalence des mĂ©dicaments gĂ©nĂ©riques
Fait Ă  Rabat, le 21 rejeb 1433 (12 juin 2012) et se compose de 10 articles.  - (doc, 47 Kb)
 LOI EN VERSION ARABE
Arabic version  - (doc, 220 Kb)
 Politique de MĂ©dicament du Ministere de la Sante Maroccaine
politique de mĂ©dicament  
 Retrait des mĂ©dicaments Ă  base de Dextropropoxyphène
Le 26 Novembre 2010 et suite Ă  la publication des rĂ©sultats des dernières Ă©tudes menĂ©es au sujet de la prescription des mĂ©dicaments Ă  base du principe actif « dextropropoxyphène », mettant en cause le risque de toxicitĂ© cardiaque, le Ministère de la SantĂ© a rĂ©uni d?urgence la Commission Nationale Consultative de Pharmacovigilance et a dĂ©cidĂ© le retrait de toutes les spĂ©cialitĂ©s pharmaceutiques Ă  base de Dextropropoxyphène.  

 

 

 

This page does not yet have information.

Heath Research Web is a public platform for information on research for health and development, it depends on contributions and participation from all who are interested in promoting health, health equity and development.

Please help Morocco populate its page

 

1

Choose your user profile

2

Create your account

3

Activate your account

4

Start using HRWeb
 

 

 

This page does not yet have information.

Heath Research Web is a public platform for information on research for health and development, it depends on contributions and participation from all who are interested in promoting health, health equity and development.

Please help Morocco populate its page

 

1

Choose your user profile

2

Create your account

3

Activate your account

4

Start using HRWeb
 

 

Medicines Regulation (Map)

 

www.espicom.com/morocco-pharmaceutical-market

The Pharmaceutical Market: Morocco

OVERVIEW OF THE PHARMACEUTICAL MARKET IN MOROCCO

Morocco's subsidised health insurance scheme,Régime d'Assistance Médicale (RAMED),launched in March 2012,is experiencing early-stage difficulties with its target to increasehealthcare accessibilityto those on low incomes. This is to be expected, given the evidence of bribery and corruption, and the shortage of doctors in the sector.BMIbelievesthe commitment to improvegovernance and implement controls in the sector will be fulfilled in the medium-to-longterm. As such, we maintainthat government healthcare spending will outpace private healthcare spending over the forecast 2011-2016 period.

Headline Expenditure Projections

Pharmaceuticals: MAD10.10bn (US$1.25bn) in 2011 to MAD11.24bn (US$1.30bn) in 2012; +11.3% in local currency terms and +4.5% in US dollar terms. Forecastbroadly unchangedfrom Q412.

Healthcare: MAD41.99bn (US$5.19bn) in 2011 to MAD47.09bn (US$5.46bn) in 2012; +12.2% in local currency terms and +5.4% in US dollar terms. Forecastslightly higherfromQ412, on account of slightly lower historical figures.

Medical devices: MAD2.19bn (US$270mn) in 2011 to MAD2.47bn (US$287mn) in 2012; +13.1% in local currency terms and +6.2% in US dollar terms. Forecast broadly unchanged from Q 4 12 .


Risk/RewardRating: In Q113, Morocco remains 12th out of the 30 markets included in the MEA region. Its composite score remains unchanged, at 46.8 out of the maximum 100. The country's rewards ratings are less promising than its risks profile, which weighs down its overall score. The market is medium-sized by regional standards and small on a global scale, but its high growth potential offsets relatively low per capita drug consumption, especially in rural areas. In the risks category, Morocco scores above the regional average, indicating a relatively low level of country and pharmaceutical industry-specific risk in a somewhat volatile region.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.